Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 27 · below the Ichimoku cloud · RSI 20 (oversold) · MACD above its signal · 8% above its 52-week low
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $4.1M | 0.01% | 165.70K | +20% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BIOA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 29, 2026 | Barton ShaneOfficer | Sale at price 25.19 - 25.21 per share. | 62.6K | $1.58M |
| Jun 29, 2026 | Barton ShaneOfficer | Conversion of Exercise of derivative security at price 4.30 - 10.85 per share. | 59.9K | $394.56K |
| Apr 22, 2026 | Goldstein Dov AChief Financial Officer | Conversion of Exercise of derivative security at price 4.38 per share. | 3.5K | $15.51K |
| Mar 31, 2026 | Rubin Paul DOfficer | Sale at price 17.81 per share. | 8.8K | $157.08K |
| Mar 31, 2026 | Rubin Paul DOfficer | Conversion of Exercise of derivative security at price 4.11 - 6.57 per share. | 8.8K | $44.57K |
| Mar 1, 2026 | Rubin Paul DOfficer | Sale at price 20.30 per share. | 7.4K | $150.89K |
| Mar 1, 2026 | Rubin Paul DOfficer | Conversion of Exercise of derivative security at price 4.11 - 6.57 per share. | 7.4K | $35.47K |
| Feb 26, 2026 | Goldstein Dov AChief Financial Officer | Conversion of Exercise of derivative security at price 4.38 per share. | 3.5K | $15.51K |
| Feb 1, 2026 | Rubin Paul DOfficer | Sale at price 18.75 per share. | 7.4K | $139.37K |
| Feb 1, 2026 | Rubin Paul DOfficer | Conversion of Exercise of derivative security at price 4.11 - 6.57 per share. | 7.4K | $35.47K |
| Jan 29, 2026 | Goldstein Dov AChief Financial Officer | Conversion of Exercise of derivative security at price 4.38 per share. | 3.5K | $15.51K |
| Jan 15, 2026 | Goldstein Dov AChief Financial Officer | Conversion of Exercise of derivative security at price 4.38 per share. | 3.5K | $15.51K |
| Jan 12, 2026 | Goldstein Dov AChief Financial Officer | Sale at price 18.43 - 21.08 per share. | 27K | $531.83K |
| Jan 12, 2026 | Fortney KristenChief Executive Officer | Sale at price 18.12 per share. | 233.1K | $4.22M |
| Jan 12, 2026 | Goldstein Dov AChief Financial Officer | Conversion of Exercise of derivative security at price 8.39 per share. | 27K | $226.53K |
| Jan 1, 2026 | Rubin Paul DOfficer | Sale at price 12.85 per share. | 7.4K | $95.49K |
| Jan 1, 2026 | Rubin Paul DOfficer | Conversion of Exercise of derivative security at price 4.11 - 6.57 per share. | 7.4K | $35.47K |
| Dec 8, 2025 | Rubin Paul DOfficer | Sale at price 12.00 per share. | 18K | $216.00K |
| Dec 8, 2025 | Rubin Paul DOfficer | Conversion of Exercise of derivative security at price 6.57 per share. | 18K | $118.26K |
| Dec 3, 2025 | Rubin Paul DOfficer | Sale at price 10.19 per share. | 68.9K | $701.91K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 43.5 | 17.3 | -21.5 | -3.7 | 2.6 | 41.8 | -63.1 | 5.1 | -25.4 | -23.3 | −58.9% | ||
| 2025 | -20.7 | 0.9 | -18.8 | 11.7 | -5.7 | 4.3 | 6.5 | 12.0 | 19.3 | 28.7 | 25.4 | 39.4 | +128.5% |
| 2024 | 13.5 | -20.3 | -69.2 | −72.2% |
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Buy / hold / sell counts